Cargando…

GLP-1 physiology informs the pharmacotherapy of obesity

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight,...

Descripción completa

Detalles Bibliográficos
Autor principal:	Drucker, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859548/ https://www.ncbi.nlm.nih.gov/pubmed/34626851 http://dx.doi.org/10.1016/j.molmet.2021.101351

Ejemplares similares

Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes
por: Wong, Gunther, et al.
Publicado: (2023)

Pharmacotherapy for Obesity
por: Joo, Jong Kil, et al.
Publicado: (2014)

Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
por: Fujiwara, Yuki, et al.
Publicado: (2019)

Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
por: Liberini, Claudia G., et al.
Publicado: (2019)

The physiological role of the brain GLP-1 system in stress
por: Holt, Marie K., et al.
Publicado: (2016)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
por: Anandhakrishnan, Ananthi, et al.
Publicado: (2016)

Current Long-Term Pharmacotherapies for the Management of Obesity
por: Kim, Bo-Yeon, et al.
Publicado: (2020)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Pharmacotherapies for Obesity: Past, Current, and Future Therapies
por: Ioannides-Demos, Lisa L., et al.
Publicado: (2011)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Obesity pharmacotherapy: current status
por: Kumar, Parveen, et al.
Publicado: (2015)

Obesity Treatment – Is Pharmacotherapy the Answer?
por: Rangbulla, Aditya Kumar
Publicado: (2020)

Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
por: Merlino, Dante J., et al.
Publicado: (2014)

Hydrogen Sulfide in the Adipose Tissue—Physiology, Pathology and a Target for Pharmacotherapy
por: Bełtowski, Jerzy, et al.
Publicado: (2016)

Cost-Effectiveness of Pharmacotherapy to Reduce Obesity
por: Veerman, J. Lennert, et al.
Publicado: (2011)

Pharmacotherapy for chronic obesity management: a look into the future
por: Abdel-Malek, Mariana, et al.
Publicado: (2023)

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection()()
por: Ussher, John R., et al.
Publicado: (2014)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
por: Rojano Toimil, Alba, et al.
Publicado: (2021)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
por: Chakhtoura, Marlene, et al.
Publicado: (2023)

Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
por: Itoh, Nobuyuki, et al.
Publicado: (2015)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling
por: Remm, Friederike, et al.
Publicado: (2018)

Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy
por: Altabas, Velimir, et al.
Publicado: (2015)

Brain GLP-1 Signaling Regulates Femoral Artery Blood Flow and Insulin Sensitivity Through Hypothalamic PKC-δ
por: Cabou, Cendrine, et al.
Publicado: (2011)

Antiglaucoma pharmacotherapy
por: Tătaru, CP, et al.
Publicado: (2012)

Pharmacotherapy of Insomnia
por: Neubauer, David N, et al.
Publicado: (2018)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
por: Quarta, Carmelo, et al.
Publicado: (2022)

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
por: McLean, Brent A., et al.
Publicado: (2021)

GLP-1 Based Combination Therapy for Obesity and Diabetes
por: Lee, Young Hee, et al.
Publicado: (2017)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion
por: Panaro, Brandon L., et al.
Publicado: (2020)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
por: Zimmermann, Tina, et al.
Publicado: (2022)

Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy
por: Moffett, R. Charlotte, et al.
Publicado: (2014)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
por: Meurot, C., et al.
Publicado: (2022)

Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
por: Drucker, Daniel J.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kt0mq10c3c09ropje35e13san9